These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

609 related items for PubMed ID: 18178361

  • 1. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
    Fritsche TR, Rhomberg PR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections.
    Fritsche TR, Rhomberg PR, Sader HS, Jones RN.
    J Antimicrob Chemother; 2008 May; 61(5):1092-8. PubMed ID: 18310135
    [Abstract] [Full Text] [Related]

  • 3. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
    Appelbaum PC.
    Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD.
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).
    Sader HS, Becker HK, Moet GJ, Jones RN.
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377
    [Abstract] [Full Text] [Related]

  • 6. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
    Sader HS, Jones RN, Rossi KL, Rybak MJ.
    J Antimicrob Chemother; 2009 Nov; 64(5):1024-8. PubMed ID: 19744978
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [Abstract] [Full Text] [Related]

  • 8. [Investigation of glycopeptide resistance in methicillin resistant staphylococcal isolates].
    Hoşgör Limoncu M, Ermertcan S, Taşli H, Kurutepe S.
    Mikrobiyol Bul; 2007 Oct; 41(4):511-6. PubMed ID: 18173069
    [Abstract] [Full Text] [Related]

  • 9. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital.
    Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hasçelik G.
    J Antimicrob Chemother; 2005 Sep; 56(3):519-23. PubMed ID: 16046461
    [Abstract] [Full Text] [Related]

  • 10. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.
    Sader HS, Fritsche TR, Jones RN.
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2330-6. PubMed ID: 16801409
    [Abstract] [Full Text] [Related]

  • 11. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G, White R, Friedrich L.
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [Abstract] [Full Text] [Related]

  • 12. Key considerations in the treatment of complicated staphylococcal infections.
    Jones RN.
    Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus.
    Park YS, Shin WS, Kim SK.
    J Antimicrob Chemother; 2008 Jan; 61(1):163-8. PubMed ID: 17967852
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.
    Appleman MD, Citron DM.
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):441-4. PubMed ID: 20226335
    [Abstract] [Full Text] [Related]

  • 15. In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006).
    Hatano K, Matsuzaki K, Sato Y, Kobayashi I, Yamaguchi K.
    J Antibiot (Tokyo); 2007 Nov; 60(11):709-12. PubMed ID: 18057701
    [Abstract] [Full Text] [Related]

  • 16. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS, Skinner R, Lewis SR, Krause KM, Blais J, Benton BM.
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [Abstract] [Full Text] [Related]

  • 17. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 1997 Aug 22; 46(33):765-6. PubMed ID: 9272582
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection.
    Rouse MS, Steckelberg JM, Patel R.
    Diagn Microbiol Infect Dis; 2007 Jul 22; 58(3):363-5. PubMed ID: 17449212
    [Abstract] [Full Text] [Related]

  • 19. Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci.
    Franchi D, Climo MW, Wong AH, Edmond MB, Wenzel RP.
    Clin Infect Dis; 1999 Dec 22; 29(6):1566-8. PubMed ID: 10585815
    [Abstract] [Full Text] [Related]

  • 20. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates.
    Hussain FM, Boyle-Vavra S, Shete PB, Daum RS.
    J Infect Dis; 2002 Sep 01; 186(5):661-7. PubMed ID: 12195353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.